Duration and tension of postvaccinal pneumococcal immunity in HIV-positive patients

Abstract

Aim. To study the duration and tension of the postvaccinal pneumococcal immunity in HIV-positive patients, immunized with polysaccharide vaccine.
 Materials and methods. One hundred HIV-infected patients (age range 20 to 50 years) with stages 3 and 4 A of disease, having the number of CD4+ T-lymphocytes in blood not less than 440 mcl–1, were immunized with polysaccharide 23-valent pneumococcal vaccine.
 Results. The maximum effect regarding polysaccharide pneumococcal vaccine immunization of HIV-positive persons was established at the stage 3 of disease. When immunizing HIV-positive patients with stage 4 A and decrease in CD4+- T-lymphocytes to 310 [300; 330] cells per mcl-1, the effect resulting from immunization reduced.
 Conclusions. Taking into account the revealed maximum effect of immunization of HIV-positive patients with polysaccharide pneumococcal vaccine at the stage 3 of disease, this risk group should be immunized at the earlier periods of infectious process development. HIV-positive patients with the stage 4 A and decrease in CD4+ – T- blood lymphocytes to 310 [300;330] cells per mcl–1 should receive antiretroviral therapy followed by revaccination.